(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 61.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.71%.
Zenas Biopharma's revenue in 2025 is $15,000,000.On average, 3 Wall Street analysts forecast ZBIO's revenue for 2025 to be $1,544,016,736, with the lowest ZBIO revenue forecast at $421,103,130, and the highest ZBIO revenue forecast at $3,789,928,170. On average, 1 Wall Street analysts forecast ZBIO's revenue for 2026 to be $721,770,765, with the lowest ZBIO revenue forecast at $721,770,765, and the highest ZBIO revenue forecast at $721,770,765.
In 2027, ZBIO is forecast to generate $2,958,460,040 in revenue, with the lowest revenue forecast at $2,464,295,517 and the highest revenue forecast at $3,452,624,563.